NASDAQ:PSTI

Pluristem Therapeutics Stock Forecast, Price & News

$4.12
-0.22 (-5.07 %)
(As of 06/15/2021 01:40 PM ET)
Add
Compare
Today's Range
$4.08
$4.27
50-Day Range
$3.54
$4.89
52-Week Range
$3.50
$12.15
Volume7,529 shs
Average Volume632,305 shs
Market Capitalization$130.77 million
P/E RatioN/A
Dividend YieldN/A
Beta2.34
30 days | 90 days | 365 days | Advanced Chart
Receive PSTI News and Ratings via Email

Sign-up to receive the latest news and ratings for Pluristem Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Pluristem Therapeutics logo

About Pluristem Therapeutics

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant's patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.38 out of 5 stars

Medical Sector

761st out of 2,100 stocks

Biological Products, Except Diagnostic Industry

104th out of 198 stocks

Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Pluristem Therapeutics (NASDAQ:PSTI) Frequently Asked Questions

Is Pluristem Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pluristem Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Pluristem Therapeutics stock.
View analyst ratings for Pluristem Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Pluristem Therapeutics?

Wall Street analysts have given Pluristem Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Pluristem Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Pluristem Therapeutics' next earnings date?

Pluristem Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, June 21st 2021.
View our earnings forecast for Pluristem Therapeutics
.

How were Pluristem Therapeutics' earnings last quarter?

Pluristem Therapeutics Inc. (NASDAQ:PSTI) issued its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.80) EPS for the quarter, beating analysts' consensus estimates of ($0.90) by $0.10.
View Pluristem Therapeutics' earnings history
.

How has Pluristem Therapeutics' stock price been impacted by Coronavirus?

Pluristem Therapeutics' stock was trading at $2.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PSTI stock has increased by 42.2% and is now trading at $4.11.
View which stocks have been most impacted by COVID-19
.

When did Pluristem Therapeutics' stock split? How did Pluristem Therapeutics' stock split work?

Pluristem Therapeutics shares reverse split on the morning of Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of Pluristem Therapeutics stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for PSTI?

4 analysts have issued 1-year target prices for Pluristem Therapeutics' shares. Their forecasts range from $6.00 to $12.50. On average, they expect Pluristem Therapeutics' share price to reach $9.88 in the next year. This suggests a possible upside of 140.3% from the stock's current price.
View analysts' price targets for Pluristem Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Pluristem Therapeutics' key executives?

Pluristem Therapeutics' management team includes the following people:
  • Mr. Zami Aberman, Exec. Chairman (Age 67, Pay $501.24k)
  • Mr. Yaky Yanay, Pres, CEO & Director (Age 50, Pay $350.29k)
  • Ms. Chen Franco-Yehuda, CFO, Treasurer & Sec. (Age 37, Pay $207.69k)
  • Mr. Lior Raviv, VP of Operations & Devel.
  • Ms. Dana Rubin, Director of Investor Relations
  • Ms. Efrat Livne-Hadass, VP of HR
  • Dr. Nitsan Halevy M.D., Chief Medical Officer

Who are some of Pluristem Therapeutics' key competitors?

What other stocks do shareholders of Pluristem Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pluristem Therapeutics investors own include Teva Pharmaceutical Industries (TEVA), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Protalix BioTherapeutics (PLX), Micron Technology (MU), Pfizer (PFE), SCYNEXIS (SCYX) and Advanced Micro Devices (AMD).

What is Pluristem Therapeutics' stock symbol?

Pluristem Therapeutics trades on the NASDAQ under the ticker symbol "PSTI."

Who are Pluristem Therapeutics' major shareholders?

Pluristem Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (11.31%), Renaissance Technologies LLC (1.04%), Meitav Dash Investments Ltd. (0.53%), Sumitomo Mitsui Trust Holdings Inc. (0.38%), Nikko Asset Management Americas Inc. (0.38%) and JPMorgan Chase & Co. (0.24%).
View institutional ownership trends for Pluristem Therapeutics
.

Which major investors are selling Pluristem Therapeutics stock?

PSTI stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC.
View insider buying and selling activity for Pluristem Therapeutics
or view top insider-selling stocks.

Which major investors are buying Pluristem Therapeutics stock?

PSTI stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Meitav Dash Investments Ltd., JPMorgan Chase & Co., Morgan Stanley, Zurcher Kantonalbank Zurich Cantonalbank, Algert Global LLC, Walleye Trading LLC, and Archford Capital Strategies LLC.
View insider buying and selling activity for Pluristem Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Pluristem Therapeutics?

Shares of PSTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pluristem Therapeutics' stock price today?

One share of PSTI stock can currently be purchased for approximately $4.11.

How much money does Pluristem Therapeutics make?

Pluristem Therapeutics has a market capitalization of $130.45 million and generates $20,000.00 in revenue each year.

How many employees does Pluristem Therapeutics have?

Pluristem Therapeutics employs 146 workers across the globe.

What is Pluristem Therapeutics' official website?

The official website for Pluristem Therapeutics is www.pluristem.com.

Where are Pluristem Therapeutics' headquarters?

Pluristem Therapeutics is headquartered at MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 3508409.

How can I contact Pluristem Therapeutics?

Pluristem Therapeutics' mailing address is MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 3508409. The biotechnology company can be reached via phone at 972747108600 or via email at [email protected]


This page was last updated on 6/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.